Further Information
HTATIP2, CC3, TIP30, HIV-1 Tat interactive protein 2, 30kDa, Tat-interacting protein (30kD), HIV-1 Tat interactive protein 2, 30 kD, HIV-1 Tat interactive protein 2, 30 kDa, FLJ26963, SDR44U1, short chain dehydrogenase/reductase family 44U, member 1
Peptide ELISA: antibody detection limit dilution 1:32000.Western Blot:Approx 28kDa band observed in lysates of cell line HeLa (calculated MW of 27.0kDa according to NP_006401.3). Recommended concentration: 0.3-1ug/ml.
- Shtivelman E. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene. 1997 May 8;14(18):2167-73.
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Aliquot and store at -20?C. Minimize freezing and thawing.
500 ug/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
The immunogen for this antibody is: AETEALSKLREDFR-C
10553
HIV-1 Tat interactive protein 2, 30kDa
HTATIP2
Homo sapiens
Liquid
NP_001091990.1, NP_006401.3, NP_001091991.1, NP_001091992.1, NP_001091993.1
148728164
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Cancer
This antibody is expected to recognise all three reported isoforms. Variants (NP_006401.3; NP_001091991.1; NP_001091992.1) encode the same isoform.
Q9BUP3